The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has reached its enrollment goal of 108,508 women, as announced ...
Trevi Therapeutics has announced that its Phase IIb CORAL trial of Haduvio in treating idiopathic pulmonary fibrosis (IPF) subjects with chronic cough, will continue with its current sample size ...
News that Trevi Therapeutics Inc. got the size just right of the phase IIb Coral trial with Haduvio (oral nalbuphine extended release) led the company’s shares (NASDAQ:TRVI) to close Dec. 12 at $3.60, ...
Robust 359 patient trial met primary endpoint with statistically significant reduction in PANSS total score at all dose levels compared to ...
In recent years, the FDA has amped up its supervision of accelerated approvals, including by requiring that confirmatory ...